PLANTATION, Fla., April 28 /PRNewswire-FirstCall/ -- Viragen, Inc.
(Amex: VRA) today announced that the Company has been added as a member of the
PCE Florida Index(TM), a market value index consisting of 199 Florida-
headquartered public companies with individual market values of less than
$250 million.
Developed with the assistance of the Roy E. Crummer Graduate School of
Business at Rollins College in Winter Park, Florida, the PCE Florida Index was
created to cover emerging Florida-based public companies. Viragen's
stockholders can track the Company's performance daily in relationship to the
index and Florida health care sector at: http://www.pceindexes.com .
For more information, please visit: http://www.Viragen.com .
About Viragen, Inc.:
Viragen is a biotechnology company specializing in the research,
development and commercialization of natural and recombinant protein-based
drugs designed to treat a broad range of viral and malignant diseases. These
protein-based drugs include natural human alpha interferon, monoclonal
antibodies and peptide drugs. Viragen's strategy also includes the
development of Avian Transgenic Technology as a biomanufacturing platform for
the large-scale, cost-effective production of therapeutic proteins.
Viragen is publicly traded on the American Stock Exchange (VRA).
Viragen's majority-owned subsidiary, Viragen International, Inc.,
is publicly traded on the Over The Counter Bulletin Board (VGNI). Viragen's
key partners and licensors include: Roslin Institute, Memorial Sloan-
Kettering Cancer Center, Cancer Research UK, University of Nottingham (U.K.),
University of Miami, America's Blood Centers and the German Red Cross.
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: (954) 233-8746
Fax: (954) 233-1414
E-mail: dcalder@viragen.com
The foregoing press announcement contains forward-looking statements that
can be identified by such terminology such as "expect," "potential,"
"suggests," "may," "will," "should," "could" or similar expressions. Such
forward-looking statements involve known and unknown risks, uncertainties and
other factors that may cause the actual results to be materially different
from any future results, performance or achievements expressed or implied by
such statements. In particular, management's expectations regarding future
research, development and/or commercial results could be affected by, among
other things, uncertainties relating to clinical trials and product
development; availability of future financing; unexpected regulatory delays or
government regulation generally; the Company's ability to obtain or maintain
patent and other proprietary intellectual property protection; and competition
in general. Forward-looking statements speak only as to the date they are
made. The Company does not undertake to update forward-looking statements to
reflect circumstances or events that occur after the date the forward-looking
statements are made.
SOURCE Viragen, Inc.
 back to top
Related links:
http://www.viragen.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-b
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Douglas Calder, Director of Communications of
Viragen, Inc., +1-954-233-8746, or fax, +1-954-233-1414 or e-mail
dcalder@viragen.com
|
